Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 3/20 | 0.41 |
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 5/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | USP9X | Q93008 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14089982 | 0.86 | MAPT (0.42) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL14090054 | 0.84 | AXL (0.44) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL14090100 | 0.83 | MAPT (0.41) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL14090004 | 0.83 | IKBKB (0.42) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL14090052 | 0.82 | POLB (0.45) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL12833882 | 0.82 | MAPT (0.45) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL14090018 | 0.82 | FYN (0.43) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL14090108 | 0.82 | IKBKB (0.41) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL14090111 | 0.82 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTHTTPTPN11 | |
| SCHEMBL14090140 | 0.81 | HTR1A (0.40) | KDM4EALDH1A1MAPTHTTPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | KDM4E 2432/4885ALDH1A1 2293/4885MAPT 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.